



We, LTT Bio-Pharma, have been applying cutting-edge science and technology to medicine for more than 30 years, have been conducting research and development to protect the health and lives of people all over the world.
Research and Development
We will introduce our original drug discovery technologies, pipeline under development, and launched drugs.
DR
Drug Repositioning
We were the first in Japan to point out the importance of DR and have been promoting drug discovery as a leading
DR company. We are also engaged in collaborative research using our own original library of approved drugs.


DDS
Drug Delivery System
Like DR, DDS contributes to early commercialization and reduced development risk. We have launched DDS new drug and are still developing new drugs using the world’s first DDS technology.
Collaborative R&D
and Consultation
Through joint development, we connect academia and pharmaceutical companies to efficiently develop pharmaceuticals.

Founding Family
創業者と創業家 / 水島徹 & 水島広子

Corporate Information
Careers
IR Information
- All
- Business Development
- Drug Discovery
- General Meeting of Shareholders
- Financial Information
- Other
-
2025.03.26
Announcement of the renewal of the business partnership agreement with Sino Biopharmaceutical Limited
-
2025.03.21
Notice of Agreement of License Term Sheet for PC-SOD in Europe
-
2025.03.18
Announcement of a presentation at the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025)
-
2025.03.18
Announcement of Membership in the Academia-based Bio/Healthcare Venture Association and Appointment of Our CEO as a Director of the Association.
-
2025.03.18
Announcement of a presentation at the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025)
-
2025.03.18
Report on the American Society of Peripheral Nerve (ASPN) 2025 Annual Meeting Presentation and Participation
-
2025.03.18
Announcement of the results of the third-phase clinical trial (physician-led clinical trial) for LT-5001
-
2025.03.18
Report on participation in BioEurope 2024
-
2025.03.26
Announcement of the renewal of the business partnership agreement with Sino Biopharmaceutical Limited
-
2025.03.18
Announcement of Membership in the Academia-based Bio/Healthcare Venture Association and Appointment of Our CEO as a Director of the Association.
-
2025.03.18
Announcement of Headquarters Relocation
-
2025.03.18
Request for notification of changes to the shareholder register, such as change of address
